Protecting America from Seasonal and Pandemic Influenza Act of 2026
- Sponsor
- Rep. Larsen, Rick [D-WA-2]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 22, 2026
Bottom line
The bill proposes a multi-faceted strategy to enhance influenza preparedness, vaccine development, supply chain resilience, and public access to medical countermeasures, backed by significant authorized federal funding.
What it actually does
This bill aims to comprehensively strengthen the United States' preparedness and response capabilities against seasonal and pandemic influenza. It establishes national goals for rapid vaccine delivery and universal vaccine development, mandates improvements to the domestic vaccine supply chain, and expands the authority and funding for key public health agencies like BARDA, ASPR, NIH, and CDC. The bill also focuses on increasing access to vaccines, therapeutics, and diagnostics across all populations, including through public communication strategies and test-to-treat programs.
Proponents argue
Proponents argue that this bill is a critical investment in national security and public health, directly addressing the devastating human and economic costs of influenza, as highlighted by past pandemics and seasonal outbreaks. They contend that strengthening domestic manufacturing, accelerating vaccine development, and combating misinformation are essential steps to ensure the nation is ready for future influenza threats, building on lessons learned from the COVID-19 pandemic.
Opponents contend
While no direct opposition is cited in the bill, potential critics might raise concerns about the substantial authorized spending, arguing it could contribute to inflationary pressures or divert funds from other critical priorities. Some might also express skepticism regarding the effectiveness of government-led communication campaigns in addressing vaccine hesitancy, preferring market-based or community-led solutions, and potentially viewing such efforts as overreach.
The bill is moderately complex due to its technical language and amendments to existing statutes, but its structured approach allows an informed reader to understand its provisions within a reasonable timeframe.
Section 3(a)
National Goal for Timely Delivery of First Doses of Finished Influenza Vaccine
This provision sets a national goal for the United States to have the capacity to deliver the first doses of a finished influenza vaccine within 12 weeks of a pandemic strain's emergence, within three years of the bill's enactment. It also requires the Secretary of Health and Human Services (HHS), ASPR, and BARDA to publish a plan to achieve this goal within six months.
Supporters argue
Supporters argue that a rapid vaccine response is paramount for mitigating the impact of future influenza pandemics, saving lives and reducing economic disruption. This goal provides a clear target for federal agencies and private partners.
Critics contend
Critics might question the feasibility of such an aggressive timeline, suggesting it could lead to rushed development or divert resources from other critical public health initiatives if not carefully managed.
Tradeoffs
The tension lies between the urgent need for rapid response and the scientific and logistical challenges of accelerating vaccine development and manufacturing while ensuring safety and efficacy.
Section 3(b)
National Goal for Universal Influenza Vaccine Development
This provision establishes a national goal to develop a universal influenza vaccine within 10 years of the bill's enactment. It requires HHS, NIH, and BARDA to publish a plan within one year, in partnership with vaccine manufacturers, including support for incremental vaccine efficacy improvements and research workforce development over five years.
Section 3(f)
Establishment of a Pandemic Influenza Medical Countermeasures Program
This section amends the Public Health Service Act to establish a dedicated program within BARDA for pandemic influenza medical countermeasures. The program supports research and development for innovative technologies, universal vaccines, broad-spectrum antivirals, and rapid diagnostics. It also ensures readiness through manufacturing support, stockpiling of virus seeds, antivirals, and testing equipment, and regular preparedness drills. Furthermore, it mandates the building and replenishment of qualified pandemic stockpiles and annual potency testing.
Section 5(c) and 5(d)
Addressing Misinformation and Disinformation & Communications Public-Private Partnership
Section 5(c) directs HHS to create partnerships to educate individuals about vaccine safety and efficacy, focusing on vulnerable populations and disseminating best practices. Section 5(d) mandates a targeted demonstration project, implemented through an independent non-profit, to increase vaccine confidence, focusing on individuals with chronic illnesses or comorbidities, supporting behavioral research, and developing multimodal communication campaigns.
Section 5(f)
Expanding Access to Influenza Treatment Through a Test-To-Treat Demonstration Program
This provision requires HHS to initiate an influenza test-to-treat demonstration project within one year, running for one seasonal influenza season. The project will be based in facilities serving vulnerable populations (e.g., long-term care, federal health centers like IHS clinics, FQHCs, VA facilities) or other appropriate locations, to test the operational feasibility and impact of such programs. A report on the project's findings must be made public.
Section 5(h)
Strategic National Stockpile and Security Countermeasure Procurements
This section mandates that HHS incorporate products needed for pandemic influenza into the Strategic National Stockpile (SNS), including dynamic management of antivirals, vendor-managed inventory of testing supplies, replenishment of aging products, and diversification of stockpiled items. It also requires the ASPR to include an assessment of influenza pandemic supplies and State-level stockpiles in the annual Medical Countermeasures Preparedness Review. A GAO study on State-level stockpiles and guidance sufficiency is also mandated.
Section 6(j)
Health Defense Operations Budget Matters
This section amends the Balanced Budget and Emergency Deficit Control Act of 1985 to designate 'health defense operations' as a category for budget adjustments, allowing Congress to designate appropriations for these operations. It also creates a 'professional bypass budget' for the Directors of CDC, NIH, and the Assistant Secretary for Preparedness and Response (ASPR), requiring them to submit annual budget estimates directly to the President for transmittal to Congress without change by the Secretary of Health and Human Services.
This section designates 'health defense operations' as a category for budget adjustments under the Balanced Budget and Emergency Deficit Control Act of 1985 and establishes a 'professional bypass budget' for the Directors of CDC, NIH, and ASPR, allowing them to submit budget estimates directly to the President for transmittal to Congress without changes from the Secretary of Health and Human Services.
Section 6(j)
Why it matters:The technical nature of budget process amendments often places them later in bills. While standard legislative practice for such changes, its placement and technical language could obscure its substantial impact on the power dynamics within HHS and the federal budget process.
Case for: Proponents argue that this mechanism ensures critical public health and preparedness funding is stable and protected from political interference or internal departmental budget shifts, providing agencies with the necessary autonomy to execute their vital missions effectively.
Case against: Critics might argue that this bypass undermines the Secretary of HHS's authority and the executive branch's ability to coordinate and prioritize health initiatives across the department, potentially leading to fragmented strategies and reduced accountability.
Estimated impact: This provision could significantly alter the budgetary power and autonomy of CDC, NIH, and ASPR regarding 'health defense operations,' potentially leading to more consistent funding for these areas but also impacting the broader HHS budget and oversight structure.